In order to establish a normal value of plasma glucagon immunoreactivity (GI) and glucagon-like immunoreactivity (GLI) during a newly adopted 75 g OGTT, 50 normals (N), 102 individuals with IGT and 20 diabetics (D) were subjected to the OGTT, and their plasma GI and GLI levels were determined at various intervals by radioimmunoassay using 2 kinds of the C-terminal region specific antibody, OAL123 and 30K, and of the antibody specific for the N-terminal and/or central region of glucagon, OAL196, respectively. The basal levels of OAL123-GI and 30K-GI and OAL196-GLI in the 3 groups were as follows; N, 114.3, 80.8, and 335.5; IGT, 107.6, 76.1, and 338.5; and D, 135.7, 76.9, and 342.2 pg/ml. After glucose administration, a significant decrease in plasma GI and increase in plasma GLI were observed in the 3 groups, although their changes from the basal levels were variable. The plasma samples of inexplicably high GI concentration were chromatographed to clarify the nature of the hyperglucagonemia. The apparent GI was mostly eluted in the Vo component, but negligibly at the 3500 mol.wt. glucagon fraction. There was a marked difference in the Vo peak depending upon the antiserum used. These facts suggest that plasma GI values are dependent on the amount of BPG present in particular samples, and the antibody used.

Adult↗

PubMedDate not supplied

Effect of 24R,25-dihydroxyvitamin D3 in experimental renal insufficiency.

This placebo-controlled study in JCL-Wistar rats showed that 100 micrograms/kg 24R,25-dihydroxyvitamin D3, when given for 12 days consecutively, restored immune function which had deteriorated following aminonucleoside-induced nephrosis. Urinary creatinine excretion in five-sixths nephrectomized rats was also shown to be increased by 10 micrograms/kg 24R,25-dihydroxyvitamin D3. Hypophosphataemic effects in both these cases of experimentally-induced renal insufficiency was also shown following administration of 24R,25-dihydroxyvitamin D3.

24,25-Dihydroxyvitamin D 3↗

PubMedDate not supplied

Effect of 24R,25-dihydroxyvitamin D3 in experimental diabetic rats.

The results are presented of a controlled study in male Wistar rats into the effects of 24R,25-dihydroxyvitamin D3 on blood glucose levels, bone calcium content and ADP-induced platelet aggregation in streptozocin-induced diabetes mellitus. Blood glucose levels were shown to be decreased by 10 micrograms/kg 24R,25-dihydroxyvitamin D3. The reduced bone calcium content associated with diabetes mellitus was returned to normal levels with both 1 and 10 micrograms/kg 24R,25-dihydroxyvitamin D3. It was also shown to exhibit dose-dependent anti-platelet activity. The data suggest that 24R,25-dihydroxyvitamin D3 might have potential as a mild therapeutic agent in the treatment of osteoporosis and platelet hyperactivity associated with diabetes mellitus.

24,25-Dihydroxyvitamin D 3↗